Tropion-Lung10 will combine dato-dxd with rilvegostomig, and focus on PD-L1 and TROP2 expression.

April will see the first big scientific meeting of the year, and could herald important data from Immutep and GSK.

A look at big oncology deals since 2016 suggests that there have been more duds than successes.

Will a TIGIT refocus see the stars finally align for the partners?

Skyscraper-08 yields a positive result that – with caveats – looks decent on a cross-trial basis too.

A domvanalimab triplet shows some promise in high PD-L1-expressing gastric cancer patients, but caveats abound.

Disclosure of BMS-986442’s second target antigen endorses Agenus, and is highly relevant for GSK and Compugen too.